Company Details

Antisense Therapeutics Ltd (ASX: ANP)

ASX Listed
ASX Listed, Research and Development
Healthcare / Life Sciences / Medical Devices

Company Information

  • Executive Summary

    Executive Summary

    Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Ionis Pharmaceuticals Inc. (formerly Isis Pharmaceuticals Inc.), a world leader in antisense drug development and commercialisation – ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug targeting the growth hormone receptor which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 an antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

  • Company Highlights

    Company Highlights

    • Advanced stage drug pipeline – 2 compounds with positive Phase II clinical results
    • Compounds licensed from global antisense technology leader, Ionis Pharmaceuticals (Nasdaq: IONS Market Capitalisation US$5 Billion)
    • ATL1103 for acromegaly
      • Phase II trial in acromegaly patients met primary endpoint with significant (p<0.0001) reduction in sIGF-I
      • Successful completed higher dose study in acromegaly patients
      • In confidential discussions with potential pharmaceutical development partners
    • ATL1102 for multiple sclerosis
      • Phase II trial in Relapsing Remitting-MS patients met primary end point with significant (p=0.01) reduction in the cumulative number of new active brain lesions compared to placebo
      • Drug significantly reduced B cell numbers – B cell targeting drugs have shown clinical benefit in relapsing and progressive forms MS
      • ANP to submit a US IND application in early 2017 for Phase IIb human trial

    Recent Key Outcomes

    • Settlement reached with previous ATL1103 licensing partner Strongbridge Biopharma
      • Total value received over 12 month partnership approximately $10 million (in the form of fees, manufactured drug product, toxicological testing and payment of costs in relation to higher dose study)
      • 8.5% reduction of the issued capital via cancellation of Strongbridge Biopharma holding
    • US and European Orphan Drug Designation granted for ATL1103
    • Successfully completed ATL1103 Higher Dose study
    • Completed manufacture of clinical supplies of ATL1102 for its further clinical development
    • Submitted application to the National Multiple Sclerosis Society in the US for grant funding to conduct clinical study in Germany in SP-MS patients
    • As part of new strategy, an intensified effort to access value adding new development pipeline opportunities to expand and leverage current business
      • Projects that…resonate with global capital markets to complement the Company’s existing product pipeline
      • Progressing executable opportunities
  • Board & Management

    Board & Management

    Mr Robert Moses

    Independent Non-Executive Chairman
    Formerly Corporate Vice President of CSL Limited. Mr. Moses draws on more than 40 years’ experience in the pharmaceutical/biotechnology industry.

    Mr Mark Diamond

    Managing Director & Chief Executive Officer
    Over 26 years’ experience in the pharmaceutical and biotechnology industry. Formerly Director, Project Planning/Business Development at Faulding Pharmaceuticals in the USA, in-licensing within Faulding’s European operation and International Business Development Manager in Australia.

    Over 26 years’ experience in the pharmaceutical and biotechnology industry. Formerly Director, Project Planning/Business Development at Faulding Pharmaceuticals in the USA, in-licensing within Faulding’s European operation and International Business Development Manager in Australia.

    Dr Graham Mitchell

    Independent Non-Executive Director
    Joint Chief Scientist for the Victorian Government Department of Environment and Primary Industries. Formerly Director of Research in the R&D Division of CSL Limited.

    Dr Gary Pace

    Independent Non-Executive Director
    Dr Pace has more than 40 years’ international experience in the development and commercialization in biotechnology/pharmaceuticals industries. Long-term board level experience with both multi-billion and small cap companies.

    Mr William Goolsbee

    Independent Non-Executive Director
    Founder, Chairman and CEO of Horizon Medical Inc. 1987 – 2002 until acquisition by UBS Private Equity. Founding Director then Chairman of ImmunoTherapy Corporation until acquisition by AVI Biopharma, Inc. (now Sarepta Therapeutics). Former Chairman...

    Founder, Chairman and CEO of Horizon Medical Inc. 1987 – 2002 until acquisition by UBS Private Equity. Founding Director then Chairman of ImmunoTherapy Corporation until acquisition by AVI Biopharma, Inc. (now Sarepta Therapeutics). Former Chairman of privately held BMG Pharma LLC and Metrodora Therapeutics.

  • Company News
  • Contact Details

    Contact Details